Want to see AU:DXB full AI Analyst Report?

Dimerix Limited (DXB) Price & Analysis

100 Followers

DXB Stock Chart & Stats

AU$0.29

>-AU$0.01(-2.00%)

At close: Jul 27 4:00 PM EDT

AU$0.29

>-AU$0.01(-2.00%)

Day’s Range― - ―

52-Week RangeAU$0.16 - AU$0.67

Previous CloseN/A

Volume265.68K

Average Volume (3M)1.28M

Market Cap

AU$174.12M

Enterprise ValueAU$107.16

Total Cash (Recent Filing)AU$16.15M

Total Debt (Recent Filing)AU$232.09K

Price to Earnings (P/E)―

Beta2.57

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding600,396,800

10 Day Avg. Volume953,737

30 Day Avg. Volume1,277,792

Financial Highlights & Ratios

PEG Ratio-0.04

Price to Book (P/B)-8.34

Price to Sales (P/S)28.29

P/FCF Ratio-2.38

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Debt BurdenLimited debt reduces interest and refinancing pressure, giving Dimerix greater flexibility to fund clinical programs. This is a durable balance-sheet advantage, although it does not offset the company’s need for external capital.

High Gross Profit Relative To RevenueThe strong gross-profit relationship suggests the underlying product economics could support attractive margins if revenue becomes repeatable. Future operating leverage remains possible, though current operating expenses prevent profitability.

Focused Lead-Program StrategyConcentrating resources on a lead therapy and related renal indications can create development focus and partnering optionality. Successful progress could support milestone, licensing, or royalty income, although commercialization remains unproven.

Bears Say

Volatile And Declining RevenueUnstable revenue indicates Dimerix has not established a durable commercial or partnership income stream. The 2026 decline weakens visibility into funding capacity and makes future results dependent on uncertain development or licensing milestones.

Persistent Deep LossesRecurring operating and net losses show that the business remains in investment mode rather than approaching self-sustaining profitability. Continued losses can increase dilution risk and require sustained access to capital or successful partnering.

Cash Burn And Negative EquityHeavy cash consumption combined with negative equity signals a fragile capital base and ongoing funding needs. This may constrain clinical execution or force financing on unfavorable terms if operating cash generation and partnerships do not improve.

Dimerix Limited News

S&P Dow Jones Indices Unveils September 2026 Rebalance of S&P/ASX Benchmarks

An update from Dimerix Limited ( ($AU:DXB) ) is now available. S&P Dow Jones Indices has announced the...

2d ago

DXB

Dimerix Seeks Trading Halt Ahead of Non-Dilutive Funding Update

An update from Dimerix Limited ( ($AU:DXB) ) is now available. Dimerix Limited has requested and received a...

4d ago

DXB

Dimerix Files 2026 Corporate Governance Disclosures with ASX

Dimerix Limited ( ($AU:DXB) ) has provided an announcement. Dimerix Limited has lodged its Appendix 4G and confirmed...

10d ago

DXB

Dimerix lifts revenue but annual loss more than doubles

Dimerix Limited ( ($AU:DXB) ) has provided an update. Dimerix Limited is a publicly listed biopharmaceutical company focused...

10d ago

DXB

Dimerix Secures US$10m Everest Payment as DMX-200 Global Strategy Advances

Dimerix Limited ( ($AU:DXB) ) has issued an announcement. Dimerix Limited, a clinical-stage biopharmaceutical company headquartered in Melbourne,...

17d ago

DXB

Dimerix Takes Control of U.S. IND for New Renal Asset DMX-652

Dimerix Limited ( ($AU:DXB) ) just unveiled an announcement. Dimerix Limited, a Melbourne-based clinical-stage biopharmaceutical company, is building...

20d ago

DXB

Dimerix highlights kidney disease pipeline and diversification strategy at Bioshares Summit

Dimerix Limited ( ($AU:DXB) ) has provided an announcement. Dimerix Limited, a clinical-stage biopharmaceutical group, is building a...

1M ago

DXB

Dimerix to Highlight Kidney Disease Pipeline Progress at TechKnow Invest Conference

The latest update is out from Dimerix Limited ( ($AU:DXB) ). Dimerix Limited will showcase its progress in...

1M ago

DXB

Dimerix Secures Long-Term U.S. Patent Protection for Phase 2 Kidney Drug DMX-652

Dimerix Limited ( ($AU:DXB) ) has shared an announcement. Dimerix Limited has secured a U.S. composition of matter...

2M ago

DXB

Dimerix Strikes Major Asian Licensing Deal for Phase 3 Kidney Drug DMX-200

Dimerix Limited ( ($AU:DXB) ) just unveiled an update. Dimerix has signed an exclusive licensing agreement granting Everest...

3M ago

DXB

DXB FAQ

What was Dimerix Limited’s price range in the past 12 months?

Dimerix Limited lowest share price was AU$0.16 and its highest was AU$0.67 in the past 12 months.

What is Dimerix Limited’s market cap?

Dimerix Limited’s market cap is AU$174.12M.

When is Dimerix Limited’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Dimerix Limited’s earnings last quarter?

Currently, no data Available

Is Dimerix Limited overvalued?

According to Wall Street analysts Dimerix Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Dimerix Limited pay dividends?

Dimerix Limited does not currently pay dividends.

What is Dimerix Limited’s EPS estimate?

Dimerix Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Dimerix Limited have?

Dimerix Limited has 600,396,800 shares outstanding.

What happened to Dimerix Limited’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Dimerix Limited?

Currently, no hedge funds are holding shares in AU:DXB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Dimerix Limited Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-35.74%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Dimerix Limited

Dimerix Limited is an Australian biopharmaceutical firm dedicated to discovering and bringing to market innovative pharmaceutical solutions for medical conditions where existing treatments are insufficient. The company's leading therapeutic candidate, DMX-200, is currently undergoing extensive clinical evaluation, including two separate Phase 3 trials targeting respiratory complications linked to COVID-19. DMX-200 is also in a distinct Phase 3 clinical trial for focal segmental glomerulosclerosis (FSGS), a severe kidney disorder, and is being developed for the treatment of diabetic kidney disease. Additionally, Dimerix is advancing DMX-700, which is intended for chronic obstructive pulmonary disease (COPD). The company's corporate headquarters are located in Fitzroy, Australia.